Estimating medical costs of gastroenterological diseases

Table 5 Utilization and costs of drugs related to gastroenterological diseases among cohorts (n = 183 976) in 2001, by the fourth level of ATC classification system

ATC code	Drug group name	No. of patients	No. of orders	Total cost
				US $	%	Cum. %
A02BA	H2-receptor antagonists	26 690	85 228	269 851	17.4%	17.4%
A02BC	Proton pump inhibitors	2 223	7 100	219 823	14.2%	31.6%
A02AF	Antacids with antiflatulents	98 197	385 623	156 244	10.1%	41.6%
A05BA	Liver therapy	3 234	12 990	113 482	7.3%	49.0%
A02AD	Combinations and complexes of aluminium,	83 569	305 357	108 399	7.0%	55.9%
	calcium and magnesium compounds
A03FA	Propulsives	46 418	140 278	108 006	7.0%	62.9%
A02AB	Aluminium compounds	20 845	50 850	71 820	4.6%	67.5%
A06AB	Contact laxatives	8 775	37 266	59 022	3.8%	71.3%
A02AG	Antacids with antispasmodics	53 966	160 086	52 394	3.4%	74.7%
A06AC	Bulk producers	2 327	5 851	47 848	3.1%	77.8%
A09AA	Enzyme preparations	15 041	37 149	35 754	2.3%	80.1%
A03AA	Synthetic anticholinergics, esters with	19 071	43 779	28 953	1.9%	82.0%
	tertiary amino group
A07EC	Aminosalicylic acid and similar agents	248	1 504	24 494	1.6%	83.6%
A03AX	Other synthetic anticholinergic agents	2 264	4 110	22 682	1.5%	85.0%
A04AA	Serotonin (5HT3) antagonists	108	375	22 612	1.5%	86.5%
A02DA	Antiflatulents	38 126	97 683	16 448	1.1%	87.5%
A03AB	Synthetic anticholinergics, quaternary	8 413	15 312	16 205	1.0%	88.6%
	ammonium compounds
A03BB	Belladonna alkaloids, semisynthetic,	20 940	39 494	15 415	1.0%	89.6%
	quaternary ammonium compounds
A06AD	Osmotically acting laxatives	513	1 485	15 401	1.0%	90.6%
A05AA	Bile acid preparations	409	1 580	15 064	1.0%	91.5%
	Others			131 330	8.5%	100.0%
	Totala	149 062	1719 500	1 551 250	100.0%

^aNumbers might not add to totals because of rounding.